Leukotrienes (LTs) derived from 5-lipoxygenase (5-LO) activity are most widely known for their actions during acute inflammation and asthma. 5-LO/LT pathway involvement in cardiovascular disease (CVD) pathogenesis has come to the forefront based on provocative human genetic/population and animal studies leading to the hypothesis that this pathway promotes atherosclerosis, abdominal aortic aneurysm, and myocardial infarction/reperfusion injury via increased leucocyte chemotaxis, vascular inflammation and enhanced permeability, and subsequent tissue/matrix degeneration. A series of pre-clinical studies have tested this hypothesis by means of genetic or pharmacological inhibition of either the LT biosynthesis axis (5-LO, 5-LO-activating protein, LTA 4 hydrolase, LTC 4 synthase) or the cognate LT receptors. Here, we summarize, compare, and analyse these animal studies and relate their findings to human disease pathogenesis. We draw a complex picture of 5-LO/LT participation in cardiovascular disorders, which is further complicated by marked differences between species. Moreover, we discuss how the cytokine footprint of the respective pathological conditions determines the expression level and hence, the contribution of components of the pathway to the overall disease state. Current knowledge implies a role for 5-LO and LTs during the early/acute phase of CVD, but our understanding of a putative 5-LO/LT involvement in more advanced stages of CVD is limited, thereby preventing simple extrapolation of findings from animal studies to humans.
Introduction
Leukotrienes (LTs) are potent lipid mediators primarily known for their roles in pathophysiological settings. Derived from the polyunsaturated fatty acid arachidonic acid (AA), LTs constitute a class of local-acting messengers in addition to the cyclooxygenase (COX)-derived prostaglandins and thromboxanes. LTs are generated primarily in leucocytes at the nuclear envelope, where activated cytosolic phospholipase A 2 liberates AA from membrane phospholipids. 5-Lipoxygenase (5-LO) interacts with a 'scaffold-like' protein designated 5-LO-activating protein (FLAP) that facilitates transfer of AA to 5-LO, for incorporation of molecular oxygen into the backbone of AA in a two-step reaction. The first reaction yields 5-hydroperoxyeicosatetraenoic acid (5-HPETE), followed by a dehydration step that results in the unstable epoxide LTA 4 . As considerable amounts of 5-HPETE may escape the active site after the first reaction, the thermodynamically stable derivative 5-hydroxyeicosatetraenoic acid (5-HETE), although structurally not a 'triene', represents a major 5-LO metabolite with minimal biological activities ( Table 1) . However, 5-HETE is a precursor of 5-oxo-ETE, an eicosanoid with potent biological functions (e.g. eosinophil chemotaxis, Table 1 ).
1 LTA 4 has a half-life of less than 3 s at physiological pH. 2 Despite the evanescent nature of LTA 4 , it can undergo transformation by several mechanisms. First, it may be transferred to soluble LTA 4 hydrolase, presumably aided by a fatty acid carrier protein. LTA 4 hydrolase opens the epoxide ring by water attack in the conjugated system, resulting in two hydroxyl groups at C-5 and C-12 and a triene structure coined LTB 4 . This derivative represents the most powerful pro-inflammatory product of 5-LO ( Table 1) . LTB 4 is exported from the cell or can potentially act in the nucleus as a modulator of transcription. 3 Second, 5-LO and FLAP may associate with membrane-integral LTC 4 synthase, 4 which conjugates LTA 4 with glutathione in a thioether bond at C-6. This derivative known as LTC 4 is exported by transporters such as the multidrug resistance-associated protein to the extracellular milieu, where it undergoes cleavage of the glutathione moiety to LTD 4 and LTE 4 by extracellular peptidases ( Figure 1 ). 5 Notably, LTC 4 , LTD 4 , and LTE 4 (referred to as cysteinyl-LTs, † Present address: Cellzome AG, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
cysLTs) have potent but distinct biological activities, first discovered in relation to allergy and asthma (Table 1) . 5, 6 The third fate of LTA 4 is the transfer (by directed export or diffusion) to adjacent cells, such as from neutrophils to platelets, allowing further metabolism to either LTs or another class of lipid mediators known as lipoxins, which possess unique biological effects (Table 1) 7 that will not be discussed here.
Besides 5-LO, there are other LOs that carry out stereospecific oxygenation at either C-12 or C-15 and their products are implicated in chemotaxis and tumorigenesis, 8, 9 but may also be subject to further metabolism, yielding products with functions in homeostasis and resolution of inflammation. 7, 9 The 12/15-LO enzyme apparently possesses both pro-inflammatory and anti-inflammatory functions and is present in some tissue macrophages but not in circulating monocytes. 9 Of importance, the expression of enzymes of the LT pathway is strictly regulated and depends on the cell type, as well as the activation state of the cell. The actions of LTs are mediated by a series of G protein-coupled receptors ( Figure 1 ). These cell-surface receptors display a tissuespecific expression pattern and are classified into receptors for LTB 4 (BLT 1 , BLT 2 ), as well as those for cysLTs, CysLT 1 , CysLT 2 , plus a newly discovered LTE 4 -specific receptor known as CysLT E that was identified in dual CysLT 1 /CysLT 2 knockout mice ( Table 2) .
10 GPR17, which binds uracil nucleotides, may be another receptor for LTD 4 LTs are best known for their pro-inflammatory activities and most investigators have considered only their detrimental effects in pathological conditions including asthma and cardiovascular disease (CVD). LT modifier drugs are in use for human asthma treatment and are in cardiovascular clinical trials. 16 However, LTs also perform important activities in antimicrobial host defence, thus linking inflammation and immunity, 17 and LTA 4 can be a precursor to anti-inflammatory and pro-resolving agents. 18 In the following paragraphs, we will review some of the recent 'variable' findings regarding LT involvement in several important cardiovascular pathological settings.
5-LO/LT pathway and atherosclerosis

Background
Atherosclerosis, a decades long process in humans starting with lipid deposition in the arterial wall and inflammatory cell recruitment into the intimal layer, is a prime contributor to CVD. 19 The contributions of inflammation and immune mechanisms to this process are now well appreciated and the risk of plaque rupture, resulting in thrombosis and subsequently myocardial infarction or stroke, is directly associated with the inflammatory cell content of the plaque. 20 -22 The potential role of LTs in atherosclerosis has been studied in various facets of the pathology using animal models, primarily in genetically engineered mice.
LO and LT receptor expression in atherosclerosis
Of circulating cells, neutrophils, eosinophils, mast cells and monocytes express 5-LO in varying levels, depending on the activation state. 23, 24 In human atherosclerotic lesions, favours oxidation of its non-heme iron to the ferric form, allowing for the execution of the catalytic reaction and eventually, LT formation ( Figure 1 ). 19 TNFa is an important early pro-atherogenic cytokine, and IL-1b is a promoter of leucocyte adhesion to endothelial cells (ECs). 20 By preventing maturation and regression of local DCs in atherosclerotic arteries, oxLDL promotes a rise in DC numbers with the capacity to release more of the pro-inflammatory Th1 cytokine IL-12. 20 Clearly, oxLDL is perceived as a 'danger signal', which induces clearance of oxLDL by macrophages, associated with a local inflammatory reaction. CysLTs produced under these conditions by macrophages or DCs activate ECs via CysLT 1 receptors. Notably, in a non-phlogistic state, ECs express predominantly CysLT 2 receptors, which is linked to enhanced NO release and vasorelaxation. 33 -36 In contrast, some pro-inflammatory conditions are connected to CysLT 2 downregulation and CysLT 1 induction, resulting in vessel contraction and blood pressure elevation. 35 This effect might occur during early to advanced atherosclerosis. SMC migration plays an important role in the initiating stages of atherogenesis. Importantly, LTB 4 activates these cells via BLT 1 receptors. 13 During progression of atherosclerosis, arterial tissue becomes responsive to cysLTs, indicating a vasoconstrictive function for CysLTs on SMCs as well. 13 
Plaque remodelling/inflammation and acute complications
As atherosclerosis progresses in humans with persisting characteristics of inflammation, 5-LO would be activated with LTB 4 acting as a chemotaxin to recruit more inflammatory cells. In macrophages, 6, 10 CysLT E (LTE 4 . LTC 4 , LTD 4 ) Eosinophil recruitment, vascular permeability 10 5-LO/LT pathway in cardiovascular disease this recruitment may be mediated by BLT 1 and BLT 2 . 13 T lymphocytes are also recruited via BLT 1 , allowing secretion of metalloproteinases upon LTB 4 stimulation and thus, promoting plaque destabilization. 13, 37 Of note, these cells are more common in the adventitial layer than in the intimal region of an inflamed artery. 38 A putative link between inflammation and adaptive immunity is further corroborated by the fact that dendritic cells are also responsive to LT stimulation. 39 As discussed above, not only cysLTs, but also LTB 4 , cause activation of ECs in the vascular wall. BLT 1 is detectable only in ECs of atherosclerotic lesions but not in normal ECs. 40 In monocytes, proinflammatory signalling (LPS, IFNg) down-regulates BLT 1 expression presumably in a negative feedback mechanism. In contrast, ECs and SMC respond with BLT 1 upregulation, thereby enhancing the pro-atherogenic effect of LT signalling. 40 -43 The action of LTs on these cells results in intimal hyperplasia. Eventually, cumulative necrosis of foam cells re-inforces the local release of pro-inflammatory 5-LO products, amplifying a cycle that presumably leads to plaque destabilization and rupture.
Animal models of atherosclerosis targeting the 5-LO/LT pathway
In 2001, genetic studies using atherosclerosis-susceptible and -resistant mouse strains identified the 5-LO gene (Alox5) as a potential candidate for atherosclerosis. 44 Subsequent studies with 4-to 6-month-old LDL receptor-deficient (LDL-R 2/2 ) mice expressing only one Alox5 allele fed an atherogenic diet for 8 weeks indicated a .90% reduction in atherosclerotic lesions. 45 These results, based on a very small study cohort (n ¼ 4), could not be corroborated in a subsequent study using larger numbers of homozygous 5-LO knockout mice. In this study, Zhao et al. 46 used 5-LO 2/2 apolipoprotein (apo)E 2/2 , as well as 5-LO 2/2 LDLR 2/2 mice on normal chow or atherogenic/western diet and examined lesions between 5 and 12 months of age, without observing any differences to the respective control mice. Only the youngest group of 5-LO 2/2 apoE 2/2 mice, fed an atherogenic diet for 2 months, showed a modest reduction (224%) in lesion area. Additional studies by Cao et al. 47 did not detect any dependence of lesion size on the presence or absence of Alox5 in apoE 2/2 mice. Male and female mice were analysed separately after 2 months of atherogenic diet, and female mice were studied after 6 months on western diet. Recently, we reported that 5-LO 2/2 mice on an apoE 2/2 background fed normal chow diet for 6 months had a similar atherosclerotic burden as apoE 2/2 control mice, but a slight synergistic effect toward reduced lesions was apparent with concomitant 12/15-LO deficiency. 24 However, these differences were only observed in female but not in male mice, indicating gender-specific roles for LOs in atherosclerosis. Studies targeting 5-LO are summarized in Table 3 . On the basis of recent findings about gender-dependent regulation of 5-LO activity and the differential effect of sex hormones on 5-LO pre-activation, 48 future studies will have to address the roles of these enzymes in atherosclerosis with particular focus on gender-specific effects. Pharmacological studies with 5-LO inhibitors have yielded mixed results ( Table 4) . L739010 supplied in an atherogenic diet for 8 weeks was without effect in apoE deficient male and female mice. 47 However, in LDLR 2/2 male mice treated with ZD4407 for 15
weeks, a reduction of 40% in the intima-media thickness was detected compared with untreated controls. 49 A dual COX/5-LO inhibitor, licofelone, had similar effects and reduced inflammation in atherosclerotic rabbits. 50 More convincing evidence for a role of the 5-LO CysLT 1 inhibition by montelukast appears to mimic these effects in apoE/LDLR double deficient mice or rabbits fed atherogenic diet. 57, 58 An overview of preclinical studies in mice targeting other components of the 5-LO/LT pathway is given in Table 4 . Interestingly, studies addressing the role of 12/15-LO have yielded similar variable results. Murine studies have most often reported beneficial effects of 12/15-LO deletion on atherosclerotic plaque formation, 59 and enhanced atherosclerosis when 12/15-LO or human 15-LO was overexpressed (reviewed elsewhere 9 ). Some studies used only male mice, 60 whereas we most recently only found reductions in lesion size of female mice. 24 On the other hand, rabbits overexpressing 15-LO in macrophages showed a marked reduction of lesion area. 9 These data have led to a hypothesis focusing on concentration-dependent PPARg regulation by 12/15-LO products. PPARg agonists reduce vascular inflammation via, among other things, raising NO production and reducing IL-12p40 release. 9 In in vitro studies, high levels of 12/15-LO metabolites 15-HETE and 13-HODE were required to activate PPARg, and transgenic rabbits producing more 12/15-LO products exhibited enhanced vascular protection. In contrast, low levels of the 12/15-LO-derived 13-H(P)ODE isomers were shown to suppress PPARg activation indirectly via MAPK activation. 9 These observations give rise to a concept where low or normal levels of 12/15-LO expression and activity increase risk for vascular pathology, whereas high levels of 12/15-LO products may activate PPARg and thus, are vascular protective. The actual situation is, however, likely more complicated, as not only the expression level of 12/15-LO is important, but also factors that regulate its product profile (note opposing effects of 13-HODE vs. 15-HETE on PPARg activation 61 ) and the individual cell/tissue type play a role. 9 Thus, currently the effect of 12/15-LO in atherosclerosis can only be defined for the individual model system, and results are not easily transferable to human physiology. In summary, with respect to the impact of the 5-LO pathway, the time point of atherosclerotic lesion assessment seems crucial. Effects of inhibiting the LT cascade have been apparent primarily in some short-term studies, whereas the majority of longer studies did not detect any effect of 5-LO inhibition. The presently available data suggest a role for the LT pathway during early atherosclerosis and implies that targeting the LT pathway in the early stages of disease progression might be advantageous. In the next section, we offer a rationale for this hypothesis based on cytokine regulation of LT-pathway proteins.
The 5-LO/LT pathway in atherosclerosis: a regulatory role for cytokines?
Murine models of atherosclerosis represent accelerated disease development with an early, acute inflammatory phase that progresses to an advanced state with characteristics of chronic inflammation. In this rapid atherogenic process, oxLDL-activated macrophages participate in Th1 cytokine expression. Notably, the most commonly used mouse models are on a C57BL/6 background, which is characterized by a strong Th1 and less prominent Th2 immune response. 62 The majority of CD4 þ T cells identified in early atherosclerotic lesions are of the Th1 phenotype, 63 which may primarily reflect their interaction with oxLDL-presenting macrophages or DCs via T-cell receptor-MHC II complex recognition, 64 
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would not be expected to occur in advanced atherosclerotic lipid-laden lesions with entrapped macrophages/foam cells, accelerated leucocyte apoptosis and consequent chronic inflammation. Defects in the signalling pathways or the biosynthesis of pro-resolving agents or impaired receptor function, promoted by aberrant cytokine signalling in advanced lesions, might be the underlying cause for chronic inflammatory mechanisms to prevail over pro-resolving processes.
18,69
Limitations of animal models
Animal models potentially bear the risk of compensatory mechanisms due to genetic modification of the target gene that render the results difficult to interpret. Another caveat is species differences between mice and humans. For instance, 5-LO expression in intimal atherosclerotic lesions varies between mice and humans; also, 5-LO and 12/15-LO appear to be differentially regulated in inflammatory cells of mice and humans with the murine 12/15-LO producing mainly 12-HPETE, while its human counterpart primarily synthesizes 15-HPETE. Notably, both products may have opposing effects in inflammation. 8 Moreover, atherogenesis in mice differs in several facets from the human pathology. Thus, T cells, whose presence in all stages of atherosclerotic lesions is acknowledged, are underrepresented in murine models of atherosclerosis. 70, 71 Despite these shortcomings, animal models afford an invaluable means to study the effects of directed genetic overexpression, deletion or pharmacological inhibition of key enzymes of the LT cascade in a physiological setting that cannot be achieved in humans.
5-LO/LT pathway disparities between murine and human atherosclerosis
Advanced human plaques show differences in 5-LO expression compared with mouse lesions. In human lesions, 5-LO þ cells were identified in macrophages, DCs, mast cells, and neutrophils, 55 and notably, these 5-LO þ cells are present in the neointimal region, whereas in mice, they are restricted to the adventitial layer. 46 common feature between mice and humans. 46 In human atherosclerotic plaque specimens, the quantity of 5-LO þ cells even increased during progression from early to late phase coronary heart disease. 55 Moreover, the elevated 5-LO activity was found to be associated with BLT 1 -mediated matrix metalloproteinase (MMP) release from T cells, promoting plaque instability. 37 55 Taken together, in advanced human atherosclerosis, a role for 5-LO is likely, which is distinct from its role in early atherogenesis ( Figure 2 ). This presence of the 5-LO/LT pathway in advanced lesions is not found in mouse models, which might be due to: (i) rapid progression of atheroma growth in mice vs. slower, often interrupted progression in humans (i.e. initial fatty streaks might remain dormant for many years in humans, until certain factors promote the progression of some lesions into an advanced state); 74, 75 (ii) advanced human plaques display a higher degree of instability and risk to rupture than murine plaques; (iii) temporal dissociation in the Th1/Th2 'balance' at distinct lesion stages between mice and humans.
5-LO/LT pathway and abdominal aortic aneurysm pathogenesis
Aneurysm pathogenesis includes local inflammation of the aortic wall, immune cell infiltration in the adventitial layer, and medial degeneration by macrophage-derived proteases. Human aneurysm tissue 
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In a hyperlipidemic atherogenic diet-induced AAA model, 5-LO expression is found in adventitial granulomas, often clustered with 5-LO negative T cells next to an extensive vasa vasorum. 46, 76 A distinct inflammatory/immune reaction takes place at these loci. 38, 72 In this model, atherogenic diet induces the development of AAA in the subdiaphragmatic region of the abdominal aorta of apoE 2/2 mice. 46, 77 In this regard, apoE 2/2 5-LO 2/2 mice assessed after 8 weeks on atherogenic diet were largely protected against aneurysms (incidence 2 of 17 vs. 16 of 34 in control apoE 2/2 5-LO þ/þ mice). 46 5-LO may contribute to aneurysm formation through pro-inflammatory LTs via enhanced secretion or activity of MMP-2 and of the inflammatory chemokine macrophage inflammatory protein (MIP)-1a from macrophages. 46 This effect appears to be mediated by LTD 4 binding to CysLT 1 receptors on macrophages of hyperlipidemic 5-LO expressing mice, but does not occur in 5-LO-deficient counterparts. 34, 46 In the angiotensin II (AngII) AAA model, a role for LTB 4 was suggested based on a study using apoE 2/2 BLT 1 2/2 mice. In this model, AngII is infused by osmotic minipumps at the concentration of 1 mg/min/kg body weight over the course of 4 weeks. AAA develops quite rapidly, often preceded by aortic dissection and formation of a thrombus in the aortic wall, followed by a fibrotic response and enlargement of the vessel. 77 ApoE 2/2 BLT 1 2/2 mice showed a diminished AAA incidence compared with apoE 2/2 controls. 78 Matrix-destabilizing MMP-2 and MMP-9, as well as MCP-1 levels, along with leucocyte numbers, were found to be reduced in aortic tissues of apoE 2/2 BLT 1 2/2 mice, consistent with an abrogation of LTB 4 signalling, which is known to induce MCP-1 release from mononuclear leucocytes in an autocrine manner. 79, 80 Interestingly, apoE 2/2 BLT 1 2/2 mice, like apoE 2/2 5-LO 2/2 mice, 46 had lower levels of plasma MIP-1a, implying a central role for this chemokine in 5-LO-mediated aneurysm formation. Studies in other cell types indicate that LTD 4 might be responsible for MIP induction. 81 Also, pharmacological inhibition of BLT 1 with CP-105 696 reduced AAA incidence in this model. 82 Although these studies indicate a pro-active role for the 5-LO pathway in aneurysm pathogenesis, there is also evidence to the contrary. We analysed both genetic and pharmacological inhibition of the 5-LO pathway in apoE 2/2 mice using the AngII-induced model. Here, no dependence of AAA incidence on the presence or absence of 5-LO was evident. Likewise, pharmacological inhibition of FLAP with the drug MK-591 did not alter AAA formation. 83 In this study, MIP-1a was again reduced in 5-LO-deficient adventitial tissue, but this did not translate into an altered aneurysm phenotype. 83 Subtle differences in the applied models might be responsible for these disparate results. Again, the cytokine milieu might play a crucial role in the regulation of LT pathway involvement. It is known that human aortic aneurysms are dominated by Th2 signalling (IL-4/IL-5/IL-13). 84 These cytokines downregulate 5-LO pro-inflammatory activity and enhance 12/15-LO-promoted product formation, which, in physiological contexts can contribute to an antiinflammatory, pro-resolving phenotype. 7, 85 Thus, a prominent role for proinflammatory LTs cannot be envisaged during the intermediate aneurysm growth stage. Although Th2 cytokines are beneficial in terms of limiting macrophage activation and inflammation, they also promote the release of matrix-degrading MMPs from macrophages and hence, aneurysm expansion and aggravation. 19 This again differs between cell types and species, as IL-4 indeed induces MMP-12 expression in murine macrophages, whereas MMP-1/-2/-9 expressions are inhibited in human macrophages. 86 Matrix destruction is eventually accompanied by the release of pro-inflammatory Th1 cytokines, which could cause 5-LO activation. Therefore, depending on the severity of structural deterioration in growing AAA, the Th1 or the Th2 type response might dominate, resulting in an increased (Th1) or decreased (Th2) production of 5-LO-derived LTs. In the AAA model that involves infusion of the elastin-degrading enzyme elastase into a clamped infrarenal segment, it appears that both 5-LO pathway genetic disruption [either Alox5 or Alox5ap (FLAP)] and pharmacological inhibition of FLAP with MK-886 do not influence AAA development and progression. 87 In summary, the role of the 5-LO/LT pathway in murine AAA pathogenesis is somewhat ambiguous at this stage, because there is distinct variability between murine models. Permitting some speculation, 5-LO-derived LTs may contribute to the recruitment of macrophages and T cells in early AAA pathogenesis in some pre-clinical models. Enhanced Th2 signalling could abort 5-LO-mediated pro-inflammatory events and with increasing structural deterioration of the medial wall matrix tissue, inflammatory reactions expand that may or may not be dependent on 5-LO. On the basis of human tissue studies, 72 intraluminal thrombi form at AAA and upregulate expression of LT pathway enzymes, associated with LTB 4 -mediated neutrophil recruitment into the thrombi; 72 so targeting the 5-LO pathway could potentially reduce aneurysm or associated pathology. Murine AAA models, much like the atherosclerosis models mentioned above, differ from the human situation in the temporal pattern of AAA development. For instance, in AngII-induced AAA, aneurysm evolvement even precedes atherosclerotic lesion development and is evident within days, 88 which is in clear contrast to the decades long AAA development and expansion and atherosclerotic lesion progression in humans. Targeting the 5-LO pathway for treatment of AAA pathogenesis awaits further pre-clinical studies perhaps in other larger animal models.
5-LO/LT pathway and myocardial ischaemia reperfusion injury
Activated polymorphonuclear leucocytes (PMNL), an abundant source of LTs, are key players in the early pathogenesis of ischaemia-reperfusion injury. These cells adhere to ECs and initiate an inflammatory response, resulting in PMNL extravasation, secretion of pro-inflammatory and platelet-activating mediators, release of aggressive reactive oxygen species, and subsequent increase in vascular permeability and tissue damage. 89 -91 Given that the vasoactive role of cysLTs and their receptors has been known for many years, 92 -94 it is not surprising that 5-LO-derived cysLTs are involved in ischaemic injury. 91, 95 Besides enhancing microvascular constriction and vascular permeability, CysLTs also reduce myocardial contractility and cardiac output. 94 CysLTs are produced by PMNL and EC in a transcellular fashion, 90, 96 in which ECs convert PMNL-derived LTA 4 into LTC 4 via glutathione-S-transferase ( Figure 1) . 94 LTC 4 , which promotes leucocyte transmigration into tissues, 97 is increased during acute myocardial infarction. 98 Following the initial phase of neutrophil infiltration and concomitant biosynthesis of inflammatory mediators, CysLT 2 expression in the heart is upregulated. 95 As this upregulation was only apparent 48 h, but not 3 h, after reperfusion, the role for this 5 -LO/LT pathway in cardiovascular disease receptor in the post-infarct response is probably restricted to a later stage of disease aetiology. 95 Further supporting a role of 5-LO in MI, LTB 4 was shown to mediate neutrophil chemotaxis to ischaemic tissue. 99, 100 Genetic studies a few years ago provided exciting evidence that certain haplotypes of the FLAP and LTA 4 hydrolase genes (ALOX5AP and LTA4H, respectively) were associated with an increased risk of myocardial infarction/stroke. However, this excitement has been tempered more recently by a large number of genetic studies showing either no association or only modest evidence for involvement. 101 -104 In animal models, experimental ischaemia causes elevated LT production in the damaged tissue and evidence suggests that 5-LO products play a detrimental role to tissue recovery. One such feature is cysLT-mediated perivascular oedema, which directly affects cardiac functions. 94 Inhibiting LTC 4 formation and action by infusion of anaesthetized rabbits with the FLAP inhibitor BAY-x1005 caused a drastic improvement in the consequences of coronary artery ligature 72 h post-surgery compared with vehicle-infused animals (ECG recordings and mortality). 94, 105 Other 5-LO-, FLAP-, or dual 5-LO/ COX-inhibitors applied in models of myocardial infarction have shown similar beneficial effects (measuring infarct size). 106 -109 Mice overexpressing the human BLT 1 receptor displayed strongly increased leucocyte infiltration in a lung ischaemia/reperfusion model, along with increased pro-inflammatory circuits. 100 In dogs, a 5-LO inhibitor reduced infarct size and ischaemia, 110, 111 whereas an LT antagonist failed to do so in other studies. 112 No effect of LT blockade was apparent in a rat model of myocardial ischaemia. 113 Furthermore, a study using 5-LO-deficient mice, which underwent coronary artery ligation (30 min) followed by reperfusion (24 h), did not reveal any difference in infarct area between knockouts and control mice. 114 These findings show that neither a clear target-inhibition profile exists for components of the 5-LO pathway nor is there consistency over different species and models. Further complication is added by apparently organ-specific effects of 5-LO inhibition. Thus, whereas Alox5 gene disruption caused no effect on cardiac ischaemia, 114 it reduced the severity of kidney ischaemia. 115 In cerebral ischaemia, the situation is not entirely clear. 5-LO 2/2 mice did not differ from control mice in infarct size after 60 min transient or permanent oxygen deprivation. 116 On the other hand, post-ischaemic inflammation in the brain is characterized by ample recruitment of neutrophils and microglia with concomitantly elevated LT levels (reviewed elsewhere 91 ). Following reperfusion, LTC 4 levels rise particularly in the hippocampal area and forebrain. 117 In rats, cysLT levels peaked 3-24 h and 7 days post-reperfusion, indicating roles for LTs during the subacute and late/chronic phase of cerebral ischaemia pathology, 118 one of which is an increase in permeability of the bloodbrain barrier in the early response. 91 CysLT 1 and CysLT 2 receptors are expressed in the epithelium of the barrier, as well as in the brain, as determined by mRNA analysis. 91 Of importance, rats and mice treated with CysLT 1 antagonists (montelukast, ONO-1078) showed significantly reduced ischaemic brain injury under acute and chronic conditions. 91 In summary, there is some evidence to support a potential role of the 5-LO pathway in ischaemic stroke, but the reason for the failure to detect differences in cerebral infarct size of 5-LO deficient mice vs. the control group remains elusive. Organ-specific deletion or overexpression of an LT pathway component represents an advantageous methodology to resolve many inconsistent results. In this respect, we recently reported that endothelium-specific overexpression of the CysLT 2 receptor aggravates myocardial injury/reperfusion after 48 h and conversely, its inhibition via the CysLT antagonist BAY-u9773 abolished this effect. CysLT 2 overexpression was shown to enhance vascular permeability, as well as the expression of pro-inflammatory transcription factors and adhesion molecules (Egr-1, VCAM-1, ICAM), which facilitate leucocyte transmigration. 95 Taken together, animal studies have not led to a unified, unequivocal model for the LT pathway in myocardial ischaemia-reperfusion injury. The variable findings in animal models may firstly be related to the specific target of inhibition or deletion (5-LO, FLAP, LTC 4 synthase, or the LT receptors). Whereas most studies targeting 5-LO or FLAP support their role in myocardial infarction pathogenesis, studies targeting LT receptors are mixed. 94, 95 This might indicate that additional receptors than those blocked are involved in transducing the LT effects. Alternatively, pharmacological blockade might suffer from incorrect dosing or off-target actions. Future studies should involve a systematic dissection of each component within the 5-LO/LT pathway.
Conclusion and future directions
During the last few years there has been a resurgent focus on the 5-LO/LT pathway as a potential target in CVD. The complexity of the 5-LO/LT pathway participation in mechanisms contributing to CVD is evident based on the many studies alluded to in this review.
Limitations of these studies often result from the 'snapshot' punctual nature of analysing a single time point in CVD pathogenesis that makes it difficult to gain systematic insight into 5-LO-driven or -independent processes. Murine and human CVD aetiology differ with respect to the 5-LO/LT pathway, and even within murine studies, the nature of the applied model (for atherosclerosis, AAA, or ischaemia/reperfusion injury) influences the conclusions. Whereas a role for 5-LO-derived LTs in early stages of murine and human atherosclerosis, AAA, and reperfusion injury is cogent based on their effects in chemotaxis and induction of pro-inflammatory responses, the 5-LO pathway appears to play a distinct role in advanced human atherosclerosis but not in advanced murine disease. Targeting specific LT G protein-coupled receptors rather than upstream targets involved in LT synthesis may be a superior strategy for future CVD therapeutic interventions based on extensive past experience with other pathways (e.g. via angiotensin II and adrenergic receptors), although this remains to be determined. Conditional knockouts and comprehensive translational studies should serve better than the traditional, simplistic 'one model' approach to understand the complex effects exerted by 5-LO products. Understanding the cytokine milieu during distinct stages of CVD progression will be crucial to elucidate how the expression of members of the 5-LO/LT pathway is regulated. There is little doubt that 5-LO plays important roles in many facets of CVD, but the challenge for future studies will be to clearly dissect these activities in a temporal and cell-and tissue-specific context in order to provide a solid basis for potential therapeutic interventions. 
